Fig. 2From: Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Studya Proportion of Patients with ≥ 50% Reduction in MMD over 3 months versus baseline b Proportion of CM-Patients with MMD reduction of ≥ 50% versus ≥ 30% over 3 months versus baselineBack to article page